Min Ji Byun

Min Ji Byun

Auto-generated profile, based on publicly available information

Min Ji Byun

Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Biomaterials Research
Verified
Journal Article
Open access
HSHee Seung Seo
Hee Seung Seo
JHJun-Hyeok Han
Jun-Hyeok Han
JLJaesung Lim
Jaesung Lim
GBGa-Hyun Bae
Ga-Hyun Bae
MBMin Ji Byun
Min Ji Byun
CPChun Gwon Park
Chun Gwon Park
Background: Cancer recurrence and metastasis are major contributors to treatment failure following tumor resection surgery. We developed a novel implantable drug delivery system utilizing glycol chitosan to address these issues. Glycol chitosan is a natural adjuvant, inducing dendritic cell activation to promote T helper 1 cell immune responses, macrophage activation, and cytokine production. Effective antigen production by dendritic cells initiates T-cell-mediated immune responses, aiding tumor growth control. Methods: In this study, we fabricated multifunctional methacrylated glycol chitosan (MGC) hydrogels with extended release of DNA/doxorubicin (DOX) complex for cancer immunotherapy. We constructed the resection model of breast cancer to verify the anticancer effects of MGC hydrogel with DNA/DOX complex. Results: This study demonstrated the potential of MGC hydrogel with extended release of DNA/DOX complex for local and efficient cancer therapy. The MGC hydrogel was implanted directly into the surgical site after tumor resection, activating tumor-related immune cells both locally and over a prolonged period of time through immune-reactive molecules. Conclusions: The MGC hydrogel effectively suppressed tumor recurrence and metastasis while enhancing immunotherapeutic efficacy and minimizing side effects. This biomaterial-based drug delivery system, combined with cancer immunotherapy, can substantial improve treatment outcomes and patient prognosis.

5 December 2023 in Small
Verified
Journal Article
Closed access
MBMin Ji Byun
Min Ji Byun
HSHee Seung Seo
Hee Seung Seo
Joonghak LeeJoonghak Lee
Joonghak Lee
KBKitae Ban
Kitae Ban
SOSerim Oh
Serim Oh
CPChun Gwon Park
Chun Gwon Park